grifols sa - GIKLY

GIKLY

Close Chg Chg %
6.01 0.14 2.38%

Closed Market

6.16

+0.14 (2.38%)

Volume: 214.00

Last Updated:

Nov 12, 2025, 9:47 AM EDT

Company Overview: grifols sa - GIKLY

GIKLY Key Data

Open

$6.16

Day Range

6.16 - 6.16

52 Week Range

4.15 - 7.49

Market Cap

$5.42B

Shares Outstanding

844.57M

Public Float

N/A

Beta

0.78

Rev. Per Employee

N/A

P/E Ratio

21.07

EPS

$0.31

Yield

110.00%

Dividend

$0.07

EX-DIVIDEND DATE

Aug 12, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

40.10

 

GIKLY Performance

No Data Available

GIKLY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About grifols sa - GIKLY

Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. It operates through the following segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma Segment includes all activities related with products deriving from human plasma for therapeutic use. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols i Roig in 1909 and is headquartered in Barcelona, Spain.

GIKLY At a Glance

Grifols SA
Avinguda de la Generalitat, 152-158
Barcelona, Catalonia 08174
Phone 34-93-571-22-00 Revenue 7.80B
Industry Pharmaceuticals: Major Net Income 169.74M
Sector Health Technology 2024 Sales Growth 9.47%
Fiscal Year-end 12 / 2025 Employees 23,833
View SEC Filings

GIKLY Valuation

P/E Current 21.075
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 37.979
Price to Sales Ratio 0.826
Price to Book Ratio 1.058
Price to Cash Flow Ratio 6.60
Enterprise Value to EBITDA 10.52
Enterprise Value to Sales 2.279
Total Debt to Enterprise Value 0.536

GIKLY Efficiency

Revenue/Employee 327,343.051
Income Per Employee 7,122.012
Receivables Turnover 8.70
Total Asset Turnover 0.34

GIKLY Liquidity

Current Ratio 2.656
Quick Ratio 1.005
Cash Ratio 0.454

GIKLY Profitability

Gross Margin 36.464
Operating Margin 15.59
Pretax Margin 5.646
Net Margin 2.176
Return on Assets 0.74
Return on Equity 2.709
Return on Total Capital 1.087
Return on Invested Capital 1.071

GIKLY Capital Structure

Total Debt to Total Equity 156.386
Total Debt to Total Capital 60.996
Total Debt to Total Assets 42.963
Long-Term Debt to Equity 147.53
Long-Term Debt to Total Capital 57.542
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Grifols Sa - GIKLY

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
5.83B 6.37B 7.13B 7.80B
Sales Growth
-4.22% +9.30% +11.82% +9.47%
Cost of Goods Sold (COGS) incl D&A
3.69B 4.17B 4.62B 4.96B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
425.24M 428.65M 477.76M 473.67M
Depreciation
283.11M 298.70M 318.61M 329.07M
Amortization of Intangibles
142.13M 129.96M 159.15M 144.60M
COGS Growth
+0.79% +13.04% +10.77% +7.39%
Gross Income
2.14B 2.21B 2.51B 2.84B
Gross Income Growth
-11.75% +2.87% +13.82% +13.29%
Gross Profit Margin
+36.78% +34.62% +35.24% +36.46%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.48B 1.49B 1.71B 1.60B
Research & Development
354.09M 333.00M 357.36M 357.74M
Other SG&A
1.12B 1.15B 1.36B 1.24B
SGA Growth
+12.05% +0.56% +15.33% -6.89%
Other Operating Expense
- - - 33.30M
-
Unusual Expense
21.46M (6.62M) 4.15M (11.68M)
EBIT after Unusual Expense
645.90M 727.24M 793.62M 1.23B
Non Operating Income/Expense
19.21M 67.07M 25.93M (14.36M)
Non-Operating Interest Income
13.65M 35.58M 67.38M 48.05M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
328.58M 521.83M 645.28M 773.15M
Interest Expense Growth
+15.46% +58.81% +23.66% +19.82%
Gross Interest Expense
350.61M 548.30M 685.16M 803.20M
Interest Capitalized
22.03M 26.47M 39.88M 30.04M
Pretax Income
336.52M 272.48M 174.28M 440.46M
Pretax Income Growth
-62.99% -19.03% -36.04% +152.73%
Pretax Margin
+5.77% +4.28% +2.45% +5.65%
Income Tax
100.62M 94.70M 46.87M 250.08M
Income Tax - Current - Domestic
79.63M 110.61M 198.32M 331.28M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
20.98M (15.91M) (151.46M) (81.20M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
313.61M 284.97M 195.32M 230.19M
Minority Interest Expense
97.54M 66.07M 131.20M 60.45M
Net Income
216.07M 218.90M 64.13M 169.74M
Net Income Growth
-69.36% +1.31% -70.70% +164.69%
Net Margin Growth
+3.71% +3.43% +0.90% +2.18%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
216.07M 218.90M 64.13M 169.74M
Preferred Dividends
- - - -
-
Net Income Available to Common
216.07M 218.90M 64.13M 169.74M
EPS (Basic)
0.1585 0.1613 0.0472 0.1247
EPS (Basic) Growth
-69.22% +1.77% -70.74% +164.19%
Basic Shares Outstanding
1.36B 1.36B 1.36B 1.36B
EPS (Diluted)
0.1585 0.1613 0.0472 0.1247
EPS (Diluted) Growth
-69.22% +1.77% -70.74% +164.19%
Diluted Shares Outstanding
1.36B 1.36B 1.36B 1.36B
EBITDA
1.09B 1.15B 1.28B 1.69B
EBITDA Growth
-26.10% +5.19% +10.99% +32.49%
EBITDA Margin
+18.74% +18.03% +17.90% +21.66%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 13.70
Number of Ratings 2 Current Quarters Estimate 0.145
FY Report Date 12 / 2025 Current Year's Estimate 0.43
Last Quarter’s Earnings N/A Median PE on CY Estimate N/A
Year Ago Earnings 0.366 Next Fiscal Year Estimate 0.527
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 N/A 13 13
Mean Estimate 0.14 N/A 0.43 0.53
High Estimates 0.14 N/A 0.57 0.63
Low Estimate 0.14 N/A 0.35 0.40
Coefficient of Variance N/A N/A 15.95 14.39

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 0
OVERWEIGHT 1 1 0
HOLD 0 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Hold

Grifols Sa in the News